10-K: Xtant Medical Reports 2025 Net Income, Strategic Divestitures

Xtant Medical Holdings, Inc. achieved net income in 2025 driven by license revenue and orthobiologics sales, despite divesting Coflex/CoFix assets and international hardware business, which will impact 2026 revenues.

Summary

• Achieved net income of $4.973 million for the year ended December 31, 2025, a significant improvement from a net loss of $16.449 million in 2024.
• Total revenue increased 14% to $133.9 million in 2025, up from $117.3 million in 2024.
• License revenue contributed $18.7 million in 2025, compared to $1.5 million in 2024, but is not expected to recur in 2026 due to changes in reimbursement policies for SimpliMax and SimpliGraft products.
• Completed the sale of Coflex/CoFix products and the international hardware business (Paradigm Spine GmbH) for an aggregate purchase price of $21.4 million; these divested assets generated $20.3 million in revenue in 2025 that will not repeat in 2026.
• Gross profit margin improved to 62.9% in 2025 from 58.2% in 2024, primarily due to sales mix and greater scale.
• Identified a material weakness in internal control over financial reporting as of December 31, 2025, specifically concerning the evaluation of inventory net realizable value.
• Cash and cash equivalents and restricted cash totaled $17.3 million as of December 31, 2025, with an additional $10.7 million received on February 27, 2026, from the divestitures.
• Outstanding principal under term loan and revolving credit agreements was $14.0 million as of December 31, 2025, reduced to $11.2 million by February 27, 2026.
• Credit agreements were amended on March 26, 2026, to eliminate the minimum net revenue covenant for Q4 2025 and revise future minimum net revenue covenants to align solely with orthobiologics products.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the company achieved net income in 2025 and improved gross margins, the significant revenue headwinds projected for 2026 due to divestitures and reimbursement changes, coupled with an identified material weakness in internal controls, present considerable challenges. The strategic focus on new products and market expansion is positive, but the immediate financial outlook is pressured.

Positives

• Achieved net income of $4.973 million in 2025, a significant turnaround from a $16.449 million net loss in 2024.
• Total revenue increased 14% to $133.9 million in 2025, demonstrating growth.
• Gross profit margin improved significantly to 62.9% in 2025 from 58.2% in 2024, driven by favorable sales mix and greater scale.
• Generated $12.5 million in net cash from operating activities in 2025, a substantial improvement from using $11.9 million in 2024.
• Successfully divested Coflex/CoFix assets and the international hardware business for $21.4 million, enhancing liquidity and allowing for debt reduction.
• Reduced interest expense to $3.7 million in 2025 from $4.2 million in 2024 due to lower borrowings and debt prepayments.
• Introduced several new orthobiologics products, including nanOss Strata, CollagenX, OsteoFactor Pro, and Trivium, indicating ongoing innovation.
• Maintained key certifications (ISO 13485, MDSAP) and accreditation (AATB), demonstrating commitment to quality and regulatory compliance.
• Possesses a strong intellectual property portfolio with 46 issued biologics patents (26 U.S.) and 201 issued fixation patents (150 U.S.).

Negatives

• The $18.7 million in license revenue recognized in 2025 is unlikely to repeat in 2026, and changes in CMS reimbursement for SimpliMax and SimpliGraft products will adversely affect 2026 product revenue and gross margins.
• The divestiture of Coflex/CoFix products and the international hardware business means $20.3 million in revenue from these products in 2025 will not recur in 2026.
• Hardware product family revenue has declined in recent periods.
• Incurred increased charges for excess and obsolete inventory, including a $1.3 million charge in Q4 2025 related to the Cortera Fixation System launch.
• Identified a material weakness in internal control over financial reporting as of December 31, 2025, specifically regarding the evaluation of inventory net realizable value.
• Historically incurred significant losses and expects to continue to incur losses, with no assurance of achieving sustained profitability.
• Dependent on a limited number of third-party suppliers for products, components, and raw materials, posing supply chain risks.
• Experienced high employee turnover in past years, including management, and is dependent on key employees.
• Faces labor shortages in the Belgrade, Montana area, making it difficult to attract and retain qualified personnel and potentially increasing labor costs.
• Has significant indebtedness under credit agreements with restrictive covenants, and has had difficulty complying with these covenants in the past (e.g., minimum net revenue covenant for Q4 2025, though waived).

Risks

• Historically incurred significant losses and expects to continue to incur losses, with no assurance of sustained profitability.
• The $18.7 million in license revenue recognized in 2025 is unlikely to repeat in 2026, and changes in reimbursement for SimpliMax product will adversely impact 2026 revenues and gross margins.
• The sale of Coflex/CoFix assets and the international hardware business will adversely affect 2026 revenue.
• A substantial portion of hardware product family revenue is conducted through independent sales agents and distributors who are not controlled, and revenue from this channel has declined.
• Inability to innovate, develop, introduce, market, sell, and license new products and technologies may lead to decreased market share or product obsolescence.
• Biologics products are inherently difficult and time-consuming to manufacture, and manufacturing issues could negatively impact business and operating results.
• The biologics business is highly dependent on the availability of human donors and placentas; disruptions could harm the business.
• Some biologics products, including OsteoVive Plus, involve a heightened inherent risk of disease transmission (e.g., Mycobacterium tuberculosis), which could adversely affect business, reputation, and stock price.
• Persistent inflation, tariffs, and supply chain disruptions could result in delayed product launches, lost revenue, higher costs, and decreased profit margins.
• Faces intense competition in the markets for its products.
• The private label and original equipment manufacturer (OEM) channel involves risks and may be subject to significant fluctuation, generally with lower gross margins.
• Prior and any future acquisitions, dispositions, or business combinations involve risks that could adversely affect business, operating results, and financial condition.
• Negative publicity concerning methods of tissue recovery and screening of donor tissue in the industry could reduce demand for biologics products and impact donor supply.
• Dependence on a limited number of third-party suppliers for products, components, and raw materials.
• Highly dependent on the continued availability of its facilities in Belgrade, Montana; any unavailability could cause significant costs and disruptions.
• May be party to product liability litigation that could be expensive, and insurance coverage may not be adequate.
• Quarterly operating results are subject to substantial fluctuations, making them unreliable indicators of annual or future results.
• Ability to use net operating loss carryforwards (NOLs) to offset future taxable income is limited by Section 382 ownership changes.
• Identified a material weakness in internal control over financial reporting as of December 31, 2025.
• Failure to comply with regulations pertaining to human cells, tissues, and cellular and tissue-based products (HCT/Ps) or if products are deemed biological products requiring BLA approval.
• Loss of AATB accreditation would have a material adverse effect.
• U.S. governmental regulation (e.g., National Organ Transplant Act, Mtb draft guidance) could restrict the use or procurement of tissue.
• Manufacturing operations are required to comply with FDA and other governmental authorities' laws and regulations regarding medical devices, which is costly and could subject the company to enforcement action.
• Modifications to products may require new regulatory clearances or approvals, or may require recalls or cessation of marketing.
• Even if products are cleared or approved, they could be subject to restrictions or withdrawal from the market due to non-compliance or unanticipated problems.
• The use, misuse, or off-label use of products may harm market image or result in product liability suits or FDA sanctions.
• If products cause or contribute to a death or serious injury, or malfunction, the company will be subject to reporting regulations and likely litigation.
• Any future product recall or voluntary market withdrawal would significantly increase costs.
• Federal regulatory reforms (e.g., QMSR, overturning of Chevron doctrine) may adversely affect business and ability to sell products.
• Revenues depend upon prompt and adequate coverage and reimbursement from public and private insurers and national health systems.
• Limited staffing and dependence upon key employees; high employee turnover.
• Business is dependent on a sufficient number of qualified workers, and competition for such talent is intense, especially around Belgrade, Montana.
• Could be required to pay damages or prevented from selling products due to intellectual property lawsuits.
• May not be able to obtain or protect proprietary rights relating to products, leading to market share loss.
• Dependent on various information technology (IT) systems; failures, interruptions, or unauthorized tampering could have a material adverse effect.
• Significant indebtedness under Credit Agreements, which contain certain affirmative and restrictive covenants, with which the company has had difficulty complying at times.
• May need additional financing to satisfy future liquidity requirements, which may not be available on favorable terms or at all, reducing operational and strategic flexibility.
• Funds affiliated with Nantahala Capital Management, LLC own a significant percentage (48.8%) of common stock and can exert significant control over matters subject to stockholder approval.
• Shares of common stock are equity securities and are subordinate to outstanding indebtedness.
• The market price of common stock is extremely volatile.
• Failure to achieve financial guidance may adversely affect stock price.
• May issue additional common stock, resulting in stock ownership dilution.
• The sale or availability for sale of substantial amounts of common stock could adversely affect the market price.
• If securities analysts stop publishing research or reports about the company or downgrade common stock, trading volume and market price could decline.
• Anti-takeover provisions in organizational documents and agreements may discourage or prevent a change in control.
• Has never paid dividends and does not expect to do so in the foreseeable future.
• Worldwide economic and market conditions, including with respect to financial institutions, global wars and conflicts, and social unrest could adversely affect revenue, operating results, liquidity, and/or financial condition.
• Subject to several other general risk factors, including risks regarding outbreaks of contagious diseases.

Future Outlook

Xtant Medical anticipates that its 2026 revenues and gross margins will be adversely impacted by the non-recurrence of $18.7 million in 2025 license revenue and a portion of product revenue due to CMS reimbursement changes for SimpliMax and SimpliGraft products. Additionally, the $20.3 million in revenue generated in 2025 from the divested Coflex/CoFix assets and international hardware business will not repeat in 2026. The company plans to continue measured and targeted investments in expanding its commercial team, introducing new products like nanOss Strata, CollagenX, OsteoFactor Pro, and Trivium, expanding its distribution network, penetrating adjacent markets, and leveraging its growth platform with technology and strategic acquisitions. The company believes its current cash, anticipated operating cash flows, and available credit will meet cash requirements through at least March 2027, but may seek additional financing if market conditions are favorable.

Management Comments

• "We have recently made and intend to continue to make measured and targeted investments in the expansion of our commercial team to support our new products and maximize the reach of our broad portfolio of orthobiologics solutions."
• "We have focused and intend to continue to focus primarily on four key growth initiatives: (1) introduce new products... (2) expand our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions."
• "As discussed in more detail elsewhere in this report, we recognized $18.7 million in license revenue in 2025 that likely will not repeat in 2026 due primarily to changes in the reimbursement environment for our SimpliMax product effective January 1, 2026 and which changes also will adversely affect a portion of our product revenue in 2026. The loss of this license and product revenue will have an adverse impact on our 2026 revenues and other operating results, including in particular, our gross margins."
• "Our mission is to honor the gift of donation, by helping our patients live as full, and complete a life as possible."
• "We believe that our $17.3 million of cash and cash equivalents and restricted cash balance as of December 31, 2025, together with the $10.7 million in cash we received on February 27, 2026 from Companion Spine in connection with the Divestitures, our anticipated operating cash flows, and amounts available under our Revolving Credit Agreement with MidCap, will be sufficient to meet our anticipated cash requirements through at least the end of March 2027."

Industry Context

StockSavvy.ai notes that Xtant Medical operates in the highly competitive and rapidly evolving medical technology sector, specifically orthobiologics and spinal implants. The company's strategic focus on new product introductions and expanding its distribution network aligns with industry trends emphasizing innovation and market reach. However, the significant impact of CMS reimbursement changes on its SimpliMax and SimpliGraft products highlights the inherent regulatory risks and pricing pressures prevalent in the healthcare industry, particularly for cellular and tissue-based products. The divestiture of non-core assets suggests a strategic streamlining to focus on higher-growth areas, a common move for companies seeking to optimize their portfolio in a competitive landscape.

Comparison to Industry Standards

• Xtant Medical's gross profit margin of 62.9% in 2025 is competitive within the medical device and orthobiologics sector, which often sees high margins due to specialized products and R&D costs. For example, Medtronic plc (MDT) reported a gross margin of approximately 67% in its recent filings, while smaller, more specialized players like OrthoFix Medical Inc. (OFIX) or Globus Medical, Inc. (GMED) might have margins ranging from 65-75% for their core spinal and orthobiologics products. Xtant's margin improvement suggests operational efficiencies and a favorable product mix shift, despite the divestitures.
• The company's dependence on independent sales agents and distributors is a common model in the medical device industry, particularly for smaller companies or those entering new markets, as it allows for broader reach without the overhead of a full direct sales force. Larger competitors like Johnson & Johnson (JNJ) or Stryker Corporation (SYK) typically leverage extensive direct sales teams alongside distributor networks.
• The impact of CMS reimbursement changes on cellular and tissue-based products (CTPs) like SimpliMax and SimpliGraft is a sector-wide challenge. Many companies in the regenerative medicine space, including Bioventus Inc. (BVS) and AlloSource, face similar pressures from evolving regulatory and reimbursement landscapes, which can significantly affect product viability and revenue streams. The fixed price of $127.14 per square centimeter for skin substitutes under new CMS rules represents a significant shift that requires strategic adaptation across the industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted in the future, including commercial, product liability, intellectual property, and employment matters.
• Litigation is inherently unpredictable, and unfavorable resolutions could occur, potentially materially affecting cash flows or results of operations in any particular period.
• The company is currently subject to certain product liability litigation, which could be expensive to defend and may result in payments that exceed product liability insurance coverage.

Related Party Transactions

• On April 10, 2025, OrbiMed Sellers (affiliates of OrbiMed Advisors LLC, former majority stockholders) sold 73,114,592 shares of common stock to various purchasers, including funds affiliated with Nantahala Capital Management, LLC (a beneficial owner of more than 5% of common stock) and Carol Ann Vizirgianakis (mother of Board Chairman Stavros G. Vizirgianakis).
• To facilitate the OrbiMed share sale, the company entered into a registration rights agreement with the purchasers, agreeing to prepare and file a shelf resale registration statement, indemnify selling stockholders from certain liabilities, and pay all related fees and expenses.
• The Investor Rights Agreement with OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP terminated on April 15, 2025, following their share sale.
• Abhinav Jain and Tyler Lipschultz were appointed to the Board of Directors effective August 1, 2025, at the request of Nantahala Capital Management, LLC.
• An agreement with Stavros G. Vizirgianakis, a director and Chairman of the Board, regarding certain director nomination rights, terminated on October 7, 2024.

Stakeholder Impact

• Shareholders: Face potential dilution from future equity issuances, stock price volatility, and the impact of divestitures and reimbursement changes on future revenue and profitability. Nantahala Capital Management, LLC's significant ownership (48.8%) allows it to exert substantial control over corporate decisions.
• Employees: The company's success is dependent on retaining highly trained personnel, but it has experienced high employee turnover and faces labor shortages, particularly in Belgrade, Montana, which could lead to increased labor costs and operational constraints.
• Customers: May be affected by CMS reimbursement changes impacting product availability and pricing, and potential product recalls due to defects. The company's reliance on independent sales agents and distributors means customer relationships are partially dependent on these third parties.
• Suppliers: The company's dependence on a limited number of third-party suppliers for products, components, and raw materials exposes it to supply chain disruptions and potential manufacturing delays.
• Creditors: The company has significant indebtedness under Credit Agreements with restrictive covenants, and any failure to comply could lead to default and acceleration of debt, impacting the company's ability to service its obligations.

Next Steps

• Continue measured and targeted investments in commercial team expansion to support new products and maximize the reach of the orthobiologics portfolio.
• Introduce new products, including nanOss Strata, CollagenX, OsteoFactor Pro, and Trivium.
• Expand the distribution network.
• Penetrate adjacent markets.
• Leverage the growth platform with technology and strategic acquisitions.
• Implement measures to remediate the identified material weakness in internal control over financial reporting, specifically regarding inventory net realizable value.
• Comply with the new Quality Management System Regulation (QMSR) which takes effect in February 2026.
• Monitor and adapt to CMS reimbursement changes for cellular and tissue-based products, which will impact SimpliMax and SimpliGraft.
• Potentially seek additional financing prior to March 2027 to fund future operations and business strategy.

Key Dates

Recommendation

Xtant Medical's 2025 performance shows a positive shift to net income and improved gross margins, indicating some operational success and strategic streamlining through divestitures. However, the significant revenue headwinds projected for 2026 due to the non-recurring license revenue and divested assets, coupled with ongoing regulatory and competitive pressures, create substantial uncertainty. The identified material weakness in internal controls also warrants caution. While the company is taking steps to address these challenges and has a clear growth strategy, the immediate future presents considerable financial hurdles. A 'hold' recommendation is appropriate as investors should monitor the company's ability to mitigate the expected revenue decline and successfully execute its growth initiatives in the face of these challenges before considering further investment.

Keywords

Medical Technology, Orthobiologics, Spinal Implants, SEC Filing, 10-K, Financial Results, Divestiture, Reimbursement, Corporate Governance, Risk Factors, XTNT, Delaware, NYSE American, Healthcare, Medical Devices, Bone Graft, Spinal Fusion, Biologics, Intellectual Property, Debt, Capital Raise, Cybersecurity, Internal Controls